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Abstract  
Therapies based on circulating proangiogenic cells (PACs) have shown promise in ischemic 
disease models, but require further optimization to reach the bedside. Ischemia-associated hypoxia 
robustly increases microRNA-210 (miR-210) expression in several cell types, including endothelial 
cells (ECs). In ECs, miR-210 represses EphrinA3 (EFNA3), inducing proangiogenic responses. 
This study provides new mechanistic evidences for a role of miR-210 in PACs. PACs were 
obtained from either adult peripheral blood or cord blood. miR-210 expression was modulated with 
either an inhibitory complementary oligonucleotide (anti-miR-210) or a miRNA mimic (pre-miR-
210). Scramble and absence of transfection served as controls. As expected, hypoxia increased 
miR-210 in PACs. In vivo, migration toward and adhesion to the ischemic endothelium facilitate the 
pro-angiogenic actions of transplanted PACs. In vitro, PAC migration toward SDF-1/CXCL12 was 
impaired by anti-miR-210 and enhanced by pre-miR-210. Moreover, pre-miR-210 increased PAC 
adhesion to ECs and supported angiogenic responses in co-cultured ECs. These responses were 
not associated with changes in extracellular miR-210 and were abrogated by lentivirus-mediated 
EFNA3 overexpression. Finally, ex-vivo pre-miR-210 transfection predisposed PACs to induce 
post-ischemic therapeutic neovascularization and blood flow recovery in an immunodeficient 
mouse limb ischemia model. 
In conclusion, miR-210 modulates PAC functions and improves their therapeutic potential in limb 
ischemia.  
 
Keywords: microRNA-210; EFNA3; bone marrow-derived circulating cells; angiogenesis; limb 
ischemia; cell therapy. 
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Introduction  
It has been estimated that more than 200 million people worldwide are affected by peripheral 
arterial disease (PAD).1 Critical limb ischemia (CLI), the most serious form of PAD in the legs, 
requires foot amputation in 25% of subjects within one year from the diagnosis, and 25% of the 
patients with CLI will die during the same period.2 Revascularization unsuitability or failure results 
in more severe outcomes in terms of major amputation and mortality rates, especially in subjects 
with diabetes mellitu.3 Even if successful, revascularization does not prevent systemic 
complications (infarction or stroke).4 Regenerative medicine could offer new solutions to this 
outstanding clinical need. Restoring tissue homeostasis after an ischemic event requires the 
control of vascular and muscular protection and regeneration, involving complex multicellular 
processes brought about by cells resident in muscles [vascular endothelial cells (ECs), pericytes 
and satellite cells] and bone marrow (BM)-derived proangiogenic circulating cells].5-7 These 
concepts are at the basis of the development of cell-based therapeutic angiogenesis for patients 
suffering of PAD and CLI. The outcome of a recent meta-analysis revising the efficacy of cell 
injection in no-option CLI patients has showed that cell therapy enhances wound healing and 
reduces amputation probability by 59% and 37%, respectively.8 The therapeutic value of blood 
circulating BM-derived cells may be dependent on the abundance and quality of proangiogenic 
cells (PAC). This concept was raised by the discovery about 2 decades ago of the postnatal 
vasculogenic and angiogenic potential of a subpopulations of circulating mononuclear cells (MNCs) 
of BM origin that express CD34 and the VEGF-A receptor KDR.9 One approach to study these 
PACs, also previously known as Endothelial Progenitor Cells (EPCs), is to enrich them by culture 
using a medium containing EC growth factors. PACs are positive for CD45, CD34, CD31 and KDR 
and uptake acetylated low density lipoproteins (LDL). When injected in immunocompromised 
animal models of limb or myocardial ischemia, PACs have been reported to physically adhere to 
the endothelium and integrate in blood vessels; albeit their ability to differentiate in mature ECs is 
now considered limited. Additionally, PACs support angiogenesis via paracrine actions.10 PACs 
represent an easy accessible, ethically justifiable and valuable study model for autologous cell 
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therapy strategies.11, 12 However, the translational potential of autologous adult PACs is tempered 
by their low abundance in the circulation, difficulties to expanding the cells in vitro and the negative 
impact of associated risk factors on the cell regenerative potential.  In this context, in 2012, we 
proposed the possibility to improve the phenotype of adult PAC before transplantation by using 
microRNAs (miRs) that control intrinsic stem cell function and angiogenesis,13 but we did not 
investigate miR-210.14, 15 Umbilical cord blood (UBC) represents an alternative source of PAC. 
Indeed, PACs are more abundant in the cord blood than in the adult blood and UBC-PACs can be 
more easily expanded in culture, offering obvious advantages for performing in vivo transplantation 
studies.16, 17 Additionally, UCB-PACs can be banked for future therapeutic applications benefitting 
the donors. UCB-PACs banking can be particularly indicated in subjects born with known 
congenital defects in their heart and vasculature. These patients will enter a journey of 
investigations and often repeated surgeries and interventions and have a higher risk of developing 
ischemic disease.18  
Hypoxia, via HIF-1α, robustly increases intracellular miR-210 expression in several tissues and 
cells, including ECs.14, 15 In ECs, miR-210 activates survival pathways19-22 and enhances migratory 
and proangiogenic capacities.21, 23-30 We previously showed that miR-210 modulates EC by 
inhibiting Ephrin-A3 (EFNA3), a glycosylphosphatidyl-inositol-linked membrane-bound ligand.21 
Ephrins are a family of cell surface ligands that interact with Eph tyrosine kinases receptors to 
mediate intercellular adhesion and repulsion. Ephrin-Eph interactions guide migration and 
positioning of the cells for proper tissue patterning during vascular development and postnatal 
angiogenesis. Interestingly, even if EFNA3 is inhibited by miR-210, EFNA3 was found expressed 
at very high levels in ischemic tissues.31 In a cancer setting, it was recently shown that hypoxia 
regulates EFNA3 expression through a non-direct mechanism that involves the HIF-mediated 
transcriptional induction of a novel family of long-noncoding RNAs (lncRNAs) from the EFNA3 
locus.32 In turn, lncEFNA3 would favor EFNA3 protein accumulation acting at the post-
transcriptional level. 32 
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This study has mechanistically investigated the expression and function of miR-210 in cultured 
PACs and trialled the therapeutic potential of miR-210 overexpressing PACs in an 
immunocompromised mouse model of limb ischemia. 
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Results 
Hypoxia increases miR-210 in human PACs 
Adult PB-PACs were obtained from mononuclear cells (MNCs) of healthy donors by culture 
selection in the presence of EC growth factors-rich medium. Similar to our previous studies, 13, 33 
cultured PB-PACs were positive for CD45, CD34, Kinase Insert Domain Receptor (KDR), and 
CD14 (LPS receptor, expressed prevalently on monocytic cells) (Figure 1A). Following hypoxia, 
PB-PACs increased both the primary transcript (pri-miR-210) and mature forms of miR-210 
(Figure 1B i and ii). We tested whether hypoxia increased the secretion of mature miR-210 in the 
conditioned medium, but no significant differences were observed in either the unfractionated 
medium or in the extracellular vesicles (EVs) (Figures 1B iii and iv), suggesting some level of 
miR-210 retention in the parental cells.  
 
Modulation of miR-210 levels by pre- and anti-miR-210 
To study whether miR-210 modulation had an impact on human PAC biofunctions, we transfected 
PB-PACs with a synthetic miR-210 sequence (pre-miR-210) or chemically modified complementary 
oligonucleotides (anti-miR-210) to enhance or inhibit its levels, respectively. As shown in 
Supplementary figure I, both interventions efficiently modulated miR-210 levels of PB-PACs 
cultured.  
 
miR-210 does not modulate the expression of HIF-1α−regulated genes in PACs 
The hypoxia responsive factor HIF-1α modulates miR-210 directly 34 and it was proposed that miR-
210 regulates a feed-forward mechanism involving HIF-1α -regulated genes.35-37 However, in 
PACs, the expression of genes under the control of HIF-1α such as Glucose transporter 1 (GLUT-
1), Aldolase, Fructose-Bisphosphate C (ALDO-C), VEGF-A, and Adrenomedullin (ADM) were not 
affected by forced miR-210 expression changes (Supplementary figure II), which suggests  the 
absence of loop in which miR-210 potentiates HIF-1α activity. The data discourages the 
7 
 
speculation that such genes could mediate the responses induced by PAC expressing miR-210 in 
the adopted experimental conditions. 
 
SDF-1α-directed migration of PB-PACs is sensitive to miR-210 levels 
After an ischemic insult, chemotactic factors are released in the circulation and PB-PACs follow the 
chemokine gradient to migrating toward and home at the injured tissue.38 SDF-1α (CXCL12) is 
considered to be the prototypical pro-migratory chemokine.39 As shown in Figure 2A, we first 
validated that cultured PB-PACs migrated towards SDF-1α both in normoxic and hypoxic 
conditions. Moreover, pre-miR-210-transfected PB-PACs increased SDF-1α-directed cell migration 
both in normoxia (p=0.0032 vs. vehicle and p=0.0058 vs. SDF-1α-SCR) and in hypoxia (p=0.0004 
vs. vehicle and p=0.0013 vs. SDF-1α-SCR). Consistently, blocking miR-210 with anti-miR reduced 
PB-PAC migratory ability in the presence of the chemoattractant both under normoxia and hypoxia 
(p=0.0105 and p=0.0250 vs. SCR, respectively). The migration toward SDF-1α requires the 
activation of SDF-1α cognate receptor C-X-C chemokine receptor type 4 (CXCR-4) in the parent 
cells.40 Worth of note, hypoxia reportedly increases CXCR4 expression in progenitor cells.41 
Therefore, we verified if CXCR4 expression was changed in miR-210-transfected-PB-PACs. 
CXCR4 was effectively induced by hypoxia in PB-PACs, but not further regulated by the miR-210 
changes induced by transfection with pre- or anti-miR-210 (Supplementary figure III A&B).  
 
miR-210 modulation affects the interaction of PB-PACs and endothelial cells in co-culture 
We observed morphological changes in adult PACs overexpressing miR-210, as highlighted by the 
staining for the cytoskeletal protein phalloidin (Figure 2B), with an increased number of flat and 
round-shaped cells both in normoxic or hypoxic conditions (p=0.0176 and p=0.0358 vs. SCR, 
respectively). In addition, in miR-210-transfected PB-PACs hypoxia induced a further increase in 
the number of round-shaped cells (p=0.0493 vs. normoxia). These evidences suggest a potential 
effect of miR-210 on cell adhesion. Indeed, to support ECs in the angiogenic process, PB-PACs 
need first to adhere to the endothelium. Thus, we measured the number of PKH26 red-stained PB-
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PACs that were efficiently attached to a monolayer of human umbilical vein EC (HUVECs) after 
one hour of co-culture.  Hypoxia promoted PB-PAC adhesion to HUVECs (p=0.0311 vs. normoxia). 
Of note, miR-210 overexpression alone (p=0.0052 vs. SCR) or in combination with hypoxia 
(p=0.0313 vs. SCR) increased PACs adhesion. In addition, inhibiting miR-210 in PB-PACs with 
anti-miR prevented the enhancement of hypoxia-induced PB-PACs adhesion to ECs (Figure 3A).  
Next, we investigated the possibility that PB-PACs transfected with pre-miR-210 could better 
support HUVEC capacity to form network structures on a Matrigel layer, a model of in vitro 
angiogenesis. When HUVECs were cultured with miR-210-overexpressing PACs, they showed a 
higher networking capacity both under normoxia and hypoxia (p=0.0241 and p=0.0003 vs. SCR-
PACs, respectively) (Figure 3B). Green PKH67-labeled- miR-210-transfected-PACs locate all 
around red PKH26-labeled-HUVECs confirming their cooperation in HUVECs networking on 
Matrigel suggesting that cell-cell contact is necessary for miR-210-dependent stimulation of 
angiogenesis by PB-PACs. Supporting this hypothesis, neither the complete cell conditioned 
medium (CCM) of miR-210-transfected-PB-PACs or isolated EVs obtained from miR-210-
tranfected-PB-PACs increased EC networking (Supplementary figure IV A&B). Accordingly, the 
number of exosome-sized EVs measured by Nanosight technology was similar in CCM from SCR, 
pre-miR-210 and anti-miR-210 transfected PB-PACs (Supplementary figure IV C).  
 
EFNA3 overexpression prevents miR-210-induced migration and adhesion of PACs in vitro 
EFNA3 is directly targeted by miR-210 for repression.21, 42, 43 In ECs, miR-210 does not reduce 
mRNA level, but decreases EFNA3 protein.21 In line with that, both EFNA3 mRNA and miR-210 
were found upregulated in the ischemic brain.31 Interestingly, in hypoxic metastatic tumors, EFNA3 
protein expression was reported to be additionally regulated by HIF-induced expression of 
lncRNAs transcribed from the EFNA3 locus.32 Here, we investigated whether a similar mechanism 
occurred in PACs. Using qPCR primers able to discriminate the mRNA and lncRNA transcripts 
(Supplementary figure VA), we observed that in comparison to EFNA mRNA, lncEFNA3 
expression was negligible in PACs (data not shown). Moreover, in PACs neither hypoxia nor forced 
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miR-210 expressional changes affected the expression of EFNA3 mRNA or of lncEFNA3 (Figure 
4A i and ii). However, EFNA3 protein levels, measured by immunofluorescence staining, were 
responsive to miR-210 expression (Figure 4B). To study whether EFNA3 repression in PB-PACs 
is important for miR-210-induced migration and adhesion, we attempted to rescue EFNA3 
expression using a lentiviral vector (LV). The successful increase in EFNA3 mRNA after LV-
mediated gene transfer of PACs was confirmed by qPCR (Figure 5A&B). 
Figure 5C shows that the concomitant up-regulation of the duo EFNA3/miR-210 prevented the 
pro-migratory function of miR-210, especially in the presence of the chemoattractant SDF-1α. A 
similar effect was also observed in the cell adhesion protocol (Figure 5D), where pre-miR-210 
transfection increases PB-PACs adhesion. Interestingly, EFNA3 overexpression prevented miR-
210-induced adhesion to HUVECs (Figure 5D). EFNA3 action can be mediated by the engagement 
of its EPHA4 receptor.44 Therefore, we additionally analyzed the expression of EPHA4 in PACs. 
We could not detect any significant EPHA4 expressional change associated with PAC transfection 
of SCR, pre-miR-210 or anti-miR-210 under normoxia and hypoxia (Supplementary figure VB). 
Collectively, the above data indicate that miR-210 upregulation targets EFNA3 and this decrease is 
necessary for miR-210 pro-migratory and pro-adhesive functions. 
 
miR-210 enhances the therapeutic potential of PACs in a mouse model of limb ischemia 
For the in vivo protocol, we employed UCB-PACs. The UBC-PACs were first characterized for the 
expression of the classical markers already reported in PB-PACs (see Figure 1A). Consistently 
with the literature, a high proportion of UCB-derived cells (40%) were CD34 positive and (40%) of 
the cells were KDR positive, a lower proportion of the cells were CD45, while only few cells 
expressed CD14 (Supplementary figure VI A).17, 45 Next, we sought confirmation that the new 
model of UCB-PACs behaved similarly to PB-PACs characterized in this study. In details, UBC-
PACs responded to hypoxia with increased levels of miR-210 (Supplementary figure VI B). 
Furthermore, UCB-PACs could be efficiently transfected with pre-miR-210 or anti-miR-210, 
overexpressing or inhibiting miR-210, respectively (Supplementary figure VI C). Functionally, we 
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also verified that in UCB-PACs pre-miR-210 transfection increased the capacity to support HUVEC 
networking on Matrigel, while anti-miR-210 elicited the opposite effect (Supplementary figure VI 
D). 
Next, the therapeutic potential of UCB-PACs expressing different miR-210 levels was assessed in 
vivo. Transplantation of UCB-PACs over-expressing miR-210 into ischemic muscles improved 
post-ischemic blood flow recovery (Figure 6A) and increased microvascular density in ischemic 
muscles (Figure 6B). In this experimental setting, we did not observe therapeutic responses 
associated with injection of PACs transfected with either scrambled or anti-miR-210 
oligonucleotides (Figure 6B). Comparisons between responses induced by naïve UCB-PACs and 
EBM-2 control medium showed no difference, suggesting that the lack of therapeutic effect of 
PACs transplantation alone was not due to a negative effect of the transfection on the cell function 
(Supplementary figure VII A and B). Even if we cannot provide data on circulating miR-210 in 
immunocompromised mice receiving PAC transplantation, we measured miR-210 by qPCR in the 
plasma of in C57BL/6 mice subjected for 3 days to experimental ischemia (Supplementary figure 
VIIC). Data confirm an increase of miR-210 also in the plasma of ischemic mice.  
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Discussion 
In this investigation, we demonstrated the potential of miR-210 to improve migratory and adhesive 
abilities of PACs, with positive consequences on angiogenesis in vitro and in vivo. 
miR-210 is historically regarded as the master hypoxamiR. Indeed, endogenous miR-210 has been 
proven to be dramatically increased by hypoxia in virtually any tested cell type.14, 15 Adult and cord 
blood PACs are not exception, as demonstrated here for the first time. Since high miR-210 levels 
in ECs were associated with activation of angiogenesis, we investigated whether bearing high miR-
210 was stimulating also PAC functions, with the final goal of improving cell-based regenerative 
therapies approaches.46 Specifically, in vitro, we worked with PACs derived from two sources: adult 
PB and UCB. By contrast, for in vivo experiments, we focused on UCB-PACs, capitalizing from the 
University of Bristol research program employing perinatal material for stem cells and tissue 
engineering therapies dedicated to patients born with congenital heart defects, although, the cells 
used here were all from healthy donors. We previously characterized human adult PACs in several 
studies and demonstrated that these cells express a series of miRs that regulate angiogenesis. We 
already proved that PACs can be engineered with either anti-miRs (to miR-15a and 16) or tissue 
kallikrein to improve their migratory capacity and in vivo proangiogenic potential.13, 33 Here, we 
provide novel evidence that miR-210 overexpression enhanced PAC migration in vitro. This is 
associated with a remodeling of the cell shape and reduced EFNA3 protein expression. EFNA3 is 
a well characterized miR-210 target.21, 31, 42, 43 Gomez-Maldonado et al recently proposed that 
lncEFNA3 isoforms are induced by hypoxia and positively regulate EFNA3 expression.32 However, 
in PACs, lncEFNA3 expression was much lower than the EFNA3 mRNA and lncEFNA3 expression 
was not modulated by hypoxia or miR-210.  
Overriding the miR-210-induced EFNA3 down-modulation was shown to prevent EC 
chemotaxis/angiogenesis.21, 42 We confirmed this in PACs by simultaneously overexpressing miR-
210 and EFNA3. In details, we showed that LV-induced increase in EFNA3 were sufficient to 
contrast the pro-migratory and pro-adhesive effects induced by premiR-210 transfection in PACs. 
The data provide evidence of the importance of EFNA3-miR-210 interaction in regulating the 
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behavior of miR-210-engineered PACs. However, further experiments are needed to clarify the 
EFNA3-miR-210 relationship under physiological conditions. 
The possibility to use miR engineering to manipulate stem cells into more powerful therapeutic 
tools is attractive. We had already validated the feasibility and potential of manipulating miR-17 
expression in UCB-PACs.47 Moreover, miR-210 overexpression already proved utilitarian in 
mesenchymal stromal cells (MSCs).22, 48 miR-210 modulation was associated with increased cell 
survival, in keeping with the inhibition of the miR-210 target, caspase-8-associated protein-2.35 In 
PACs, miR-210 expressional changes did not impact cell proliferation and survival (data not 
shown), suggesting that miR-210 function is highly context-dependent.14, 49 
PACs have been shown to activate resident ECs, at least in part through vesicle-mediated transfer 
of miRs.50, 51, 52 Moreover, increased miR-210 microvesicle-associated levels have been observed 
in a variety of cell types exposed to hypoxia.42, 53-56 However, at difference with recent EV literature, 
57-60 the EV cargo of PACs did not appear to reflect miR-210 changes in the parent cells. Moreover, 
our data provide evidence against the hypothesis that PAC-released extracellular miR-210 of either 
endogenous or exogenous origin mediates the angiogenic responses to PACs. This represent a 
relevant control, because it allows us to exclude that miR-210 released by overloaded PACs after 
premiR-210 transfection could account for the response observed in ECs co-cultured with PACs. 
miR-210 overexpression in PB-PACs stimulated changes in their cytoskeleton and promoted 
angiogenesis response by co-cultured EC. However, anti-miR-210 treatment of PACs did not 
impact on this effect. While we do not have an exhaustive explanation of the underlying 
mechanisms, we speculate that the level of miR-210 necessary to promote such PAC actions are 
maintained after anti-miR-210. Another possible interpretation is that miR-210 might be sufficient, 
but not necessary for certain PB-PAC functions. It is also worth noting that the response to anti-
miR-210 might be cell-type dependent. In fact, miR-210 inhibition decreased the ability of UBC-
PACs to stimulate the capillary-like tube formation in co-cultured ECs. 
To validate in vivo the proangiogenic function played by miR-210 in PACs, we employed UCB-
PACs, which are currently considered a particularly attractive cell system for clinical application.16, 
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17 Additionally, it was reported that, in comparison with adult PACs, human UBC-PACs induce 
growth of more durable blood vessels in mouse (up to 4 months vs. 3 weeks for adult cells 
PACs).61 Moreover, data obtained studying UBC-PACs might be more easily transferred to a future 
clinical setting, since the UCB is currently an approved source of cell for regenerative therapy and 
it is banked in several countries.18 In vitro experiments confirmed that in UBC-PACs miR-210 was 
readily induced by hypoxia and that its expression stimulated the network formation by co-cultured 
ECs. Since we found that the miR-210-PACs supports angiogenesis by cell to cell contact in vitro, 
we injected the cells directly into the ischemic tissue, to allow cell contact to happen in the 
ischemic limb vasculature. We acknowledge that this site of injection creates an unfavorable 
environment for cell survival, as previously described.62 Pre-miR-210-overexpressing UBC-PACs 
increased post-ischemic reparative angiogenesis and blood flow recovery. Interestingly, the effect 
seems to be stronger on small arteriole development as compare to capillary density. We believe 
this reveals an interesting effect of miR-210-engineered PACs for which we do not have a clear 
mechanism, and that would be interesting to explore further. 
We could not measure a change of miR-210 expression in vitro in the conditioned medium or in the 
extracellular vesicles of miR-210-PACs. Nonetheless, we cannot exclude that after transplantation, 
PAC start to release miR-210, contributing to the effect on vascular repair. In line with this 
possibility, we found that endogenous cells, of not yet defined types, appear to contribute to limb 
ischemia-induced increases in circulating miR-210 levels observed in mouse PB-derived plasma. 
Naïve PB-PACs and CB-PACs have shown beneficial effects in preclinical and clinical studies.63 
We have been previously unable to replicate such responses with adult PB-PACs.13 Similarly, we 
here report absence of in vivo therapeutic responses to untreated UCB-PACs. This could be 
explained taking into account that different studies might differ for methods of cells isolation, 
surgical techniques to induce limb ischemia, animal background and sex, site of cell injection. 
Moreover, the number of cells injected in mice usually varies between 2x105 to 1x106 cells.47, 64, 65 
We injected 2x105 cells, which is at the lower boundary of the aforementioned range.  
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Altogether, our data point to miR-210 as way to improve PAC functional activities. We therefore 
propose that miR-210-engineering of PACs should be further explored as a way to improve cellular 
regenerative therapies in ischemic diseases. miR-210 overexpression in PACs and other 
regenerative cells could also aid in tissue engineering. Example scenarios of the latter would be 
using miR-210-expressing PACs to support vascularization of scaffolds, as well as of vascular and 
heart valve conducts, thus responding to the demands regenerative medicine must meet to correct 
acquired defects (like CLI and ischemic heart disease), while expanding to address the needs 
presented by surgery for congenital heart and vessels defects.  
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Materials and Methods 
Cell isolation, culture, and treatments 
Human blood circulating PACs were isolated and cultured as previously described.13, 33 form a 
small cohort of healthy subjects. The study protocol complied with principles of the Declaration of 
Helsinki, was covered by institutional ethical approval (11/2015 Cardiovascolare). For this study 25 
patients were enrolled with a mean age (SEM) of 41.5 (2.5) years. The 40% of the patients were 
male and the 60% were female. The collection of human umbilical cord blood used in this study 
was approved by the North Somerset and South Bristol Research Ethics Committee (Research 
Ethic Committee –REC- reference 11/H0107/4). A total of 11 donors were recruited at a gestational 
age comprised between 39 and 40 weeks. The cells were isolated following the same protocol than 
used for the isolation of PACs from adult peripheral blood. Briefly, human umbilical cord blood 
mononuclear cells were isolated by gradient centrifugation on Histopaque-1077 density medium 
(Sigma). For enrichment of the PACs, 1x107 mononuclear cells/well were plated on fibronectin 
(Sigma)-coated 6-well plates (BD Falcon) and cultured for 4 days in EBM-2, supplemented with 
EGM-2 MV SingleQuots, 10% FBS (EGM-2MV; Cambrex) and 1% penicillin/streptomycin. At that 
time, non-adherent cells were removed by 2 washes of PBS. Cells were then cultured for 6-8 days 
before being transfected with a non-targeting sequence, also identified as scramble, SCR, 
throughout the manuscript (AM4611, Silencer® Negative Control, Ambion), pre-miR-210-3p 
(PM10516, Ambion) or anti-miR-210-3p (AM10516, Ambion) 50nmol/L using Gensilencer 
Transfection reagent (Genlantis) using the manufacturer’s protocol. Three days after transfection, 
cells were submitted to hypoxia (5% CO2, 1% O2) for three days before being harvested for further 
analysis. In parallel experiments, we assessed the efficiency of PAC transfection by transfecting 
fluorescently-labeled miR-mimic (miR-mimic-Pe-Cy3) (Applied Biosystems). The percentage of 
transfected PACs was greater than 95%. 
Human umbilical vein endothelial cells (HUVECs) were purchased by Invitrogen and cultured in 
EBM-2 medium, supplemented with EGM-2 SingleQuots (Lonza) and 2% FBS (GIBCO).  
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RNA extraction and expressional analyses 
RNA was extracted from cultured cells using miRNeasy Mini Kit (Qiagen) following the 
manufacturer’s instructions. The concentration of total RNA was determined using the Nanodrop 
ND1000 Spectrophotometer (Thermo Scientific). RNA reverse transcription to measure miRs was 
performed with the TaqManmiR reverse transcription kit following the manufacturer’s instructions 
(Applied Biosystems). MiR-210 (hsa-mir-210, assay ID: 000512) expression was analyzed by the 
QuantStudio 6 Flex Real-Time PCR System (Applied Biosystems) and normalized to the U6 small 
nucleolar RNA (U6 snRNA, assay ID:001973). For gene expression analyses, single-strand 
complementary DNA (cDNA) was synthesized from 1 μg of total RNA using TaqMan Reverse 
Transcription reagents (Applied Biosystems). Quantitative RT-PCR was performed with the 
QuantStudio 6 Flex Real-Time PCR System (Applied Biosystems) using the following primers: 18s 
rRNA (forward: 5-CGCAGCTAGGAATAATGGAATAGG-3’; reverse: 5’-
CATGGCCTCAGTTCCGAAA-3’), CXCR4 (forward: 5’-CAGTGGCCGACCTCCTCTT-3’; reverse: 
5’- GGACTGCCTTGCATAGGAAGTT-3’); EFNA3 (forward: 5’-CTCTCCCCCAGTTCACCAT-3’; 
reverse: 5’-TGAGGGTTCTCTCCCTCAAA-3’) VEGF-A (forward: 5’-
CAACATCACCATGCAGATTATGC-3’; reverse: 5’-TCGGCTTGGCACATTTTTCTTGT-3’); ALDO 
(forward: 5’-GGCTGCCACTGAGGAGTTC3’ reverse: 5’-CTGCTGCTCCACCATCTTCT-3’) GLUT-
1 (forward: 5’-GATTGGCTCCTTCTCTGTGG-3’; reverse: 5’-TCAAAGGACTTGCCCAGTTT-3’) 
ADM (forward: 5’-GGAAGAGGGAACTGCGGATGT-3’; reverse: 5’-
GGCATCCGGATTCACCCTCCTAGC-3’). Data were normalized to 18S ribosomal RNA as an 
endogenous control. For miR-210 and gene expression, each PCR reaction was performed in 
duplicate and analyzed by the 2−ddCt method.66, 67 For the investigation of coding and non-coding 
EFNA3 isoforms and EPHA4the following primers pair were designed: coding EFNA3 (forward: 5’-
CACTCTCCCCCAGTTCACCAT -3’; reverse: 5’-CGCTGATGCTCTTCTCAAGCT-3’) non-coding 
EFNA3 (forward: 5’-AGTTTGGGCTGCGGAGAATC-3’; reverse: 5’-
GCAGACGAACACCTTCATCCT-3’); EPHA4 (forward: 5’-AGCAGCCACTCAGGCAAC-3’; reverse: 
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5’-ACGAAAATAGGGCGAAATAGAA-3’). Expression was normalized to Ubiquitin C (UCB) 
housekeeping gene.  
 
FACS analyses 
For CXCR4 analysis, PACs (2x105 cells) were stained with 5 μL of CXCR4 (APC) antibody (BD 
Biosciences). After 15 min incubation at room temperature in the dark, cells were washed, 
resuspended in PBS and analyzed. Cells were analyzed using a FACSCanto flow cytometer with 
the FACSDiva software (both from BD Biosciences).  
For the characterization of peripheral and cord blood PACs, 104 cells were incubated with human 
receptor FC block (eBioscience; 14-9161-71) for 5 min at room temperature. Cells were stained 
using 1:20 dilution of CD45-APC-Cy7 (BD Biosciences, #560178, 1:20), CD34-PE-Cy7 (BD 
Biosciences, #348811), KDR-PE (R&D System, FAB357P) and CD45/CD14-FITC/PE (BD 
Biosciences, BD Simultest 342408) in staining buffer (PBS supplemented with 0.5% bovine serum 
albumin) for 15 min at room temperature. Cells were washed twice and resuspended in staining 
buffer before being analysed on AceaNovocyte flow cytometer. Fluorescence minus one control 
were used to determine positive staining. The quantification of the antigenic profile was performed 
using the FlowJo v10 software (FlowJo, LLC).  
 
Migration assay 
For PACs migration assay 5 μm pore-size filter-equipped transwell chambers (Corning) coated 
with fibronectin 2 μg/mL were used. Cells (7.5x104) were placed in the upper chamber and allowed 
to migrate toward SDF-1α (R&D) (100 ng/mL) or vehicle (control) for 16 hours at 37°C. The cells 
on the upper part of the filter were scraped away before fixing the filter. The lower side of the filter 
(containing the migrated cells) was mounted with Vectashield containing DAPI. For each chamber, 
migrated cells were counted in 5 random fields at 20X magnification. Migration data are expressed 
as the number of cells migrated per field toward the specific chemoattractant vs. the number of 
cells migrated both in absence of stimulus and normoxia. Each experiment was performed in 
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duplicate. Fluorescence was visualized and captured using AXIO OBSERVER A1 microscope 
equipped with digital image processing software (AxioVision Imaging System), both from Zeiss. 
 
Adhesion assay 
HUVECs (2.5x104) were seeded and cultured for 24 hours in 96-well tissue culture plates (BD 
Falcon) in complete EGM2 (Lonza) with 2% FBS (GIBCO). PACs (2.5x104) were PKH26 red-
stained (Sigma, stained according to the manufacturer’s instructions) and added to the HUVECs 
layer. After one hour of co-culture at 37°C cells were washed gently with PBS and cell adhesion 
was quantified by counting adherent red fluorescent-PACs (magnification 10X). Each experiment 
was performed in duplicate. Fluorescence was visualized and captured using AXIO OBSERVER 
A1 microscope equipped with digital image processing software (AxioVision Imaging System), both 
from Zeiss. 
 
In vitro angiogenesis 
Capillary-like network formation Assay: 5x104 PACs were added to 8-well chamber slides (Nunc) 
pre-coated with 150 μL Matrigel (Becton Dickinson), together with 5x104 HUVECs in a total volume 
of 150 μL EBM- 2 (Lonza) with 0.1% bovine serum albumin (BSA) (Sigma). After 5 hours 
incubation at 37°C, PACs effect on network formation from HUVECs was measured by counting 
the number of intersection points in 10 microphotographs of random view fields (magnification 
20X). Similar assays were performed adding 50 μL cell conditioned medium (CCM) or 50 μL of 
PBS containing purified extracellular microvesicles obtained from PACs to the HUVECs in 50 μL 
EBM-2 0.1% BSA. For double stained pictures 5x104 HUVECs and 5x104 PACs were stained with 
PKH26 red and PKH67 green respectively according to the manufacturer’s advices prior to co-
culture on matrigel. The assays were performed in duplicate wells. Microphotographs were 
visualized and captured using AXIO OBSERVER A1 microscope equipped with digital image 
processing software (AxioVision Imaging System), both from Zeiss. 
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Extracellular microvesicles (EVs) isolation and quantification 
Cell conditioned medium (CCM) was processed for EV collection and ultrapurification, as 
described.68 For CCM, cells were removed by centrifugation (500g, 5 min), then CCM was clarified 
by centrifugation (2000g, 30 min followed by 12000g, 45 min at 4°C). EVs were collected by 
ultracentrifugation (110000g, 3 hours), washed in PBS and pelleted. The purified EV fraction was 
re-suspended in 100 μL PBS for use. EV purity and amount (normalized on the number of cultured 
cells) were confirmed by NanoSight technology.69 
 
Immunofluorescence analysis 
PACs were washed with PBS and fixed with 4% paraformaldehyde (Electron Microscopy 
Sciences). Cells were then incubated with 10% goat serum (Sigma) at 25˚C for 30 minutes, 
washed with PBS and incubated with a rabbit anti-EFNA3 antibody (1:300) in PBS overnight at 
4˚C. PACs were then washed with PBS and incubated with Goat anti-Rabbit IgG (H+L) Secondary 
Antibody, Alexa Fluor 555 conjugate (TermoFisher Scientific) (1:200) in PBS for 1 hour at 37˚C. 
For phalloidin staining cells were permeabilized with 0.1% Triton X-100, following fixing, then 
washed, blocked with 10% goat serum as described above and incubated 40 minutes with 
Tetramethylrhodamine B isothiocyanate conjugated phalloidin which directly binds cytoskekletal F-
actin. Fluorescence was visualized and captured using AXIO OBSERVER A1 microscope 
equipped with digital image processing software (AxioVision Imaging System), both from Zeiss. 
 
Lentiviral packaging, preparation and transduction of PACs 
Human embryonic kidney cells (HEK293T) were purchased by Sigma and cultured accordingly to 
Sigma protocols in DMEM 4.5 g/L glucose and 10% FBS (GIBCO) with sodium pyruvate 100 mM 
(100x), NEAA (100x), penicillin streptomycin (100x) (all from Sigma). The day before, 2.5x106 
HEK293T were plated in 100mm dishes (BD Flacon); when cells reached 70-80% confluence, 
fresh medium was replaced. For transfection two tubes were prepared each with CaCl2 2.5 M, 
pREV (0.64 μg), pMDL (0.64 μg), pVSVG (0.64 μg) and pEFNA3 (3.2 μg) or pCTRL (3.2 μg). Each 
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tube was then mixed with HBS 2X and incubated for 15 minutes at 25˚C. Each mixture was used 
for transfection of HEK293T. Lentivirus titration was performed by transducing HEK293T cells with 
concentrated particles in the presence of 4 μg/ml polybrene and measuring GFP expression after 3 
days by flow cytometry. Cells were then incubated overnight at 37˚C, then the medium was 
replaced and 24 hours later cells supernatants containing the virus were harvested and filtered 
using a 0.45 μm sterile filters (Millipore). 
PACs were transduced with lentivirus at 1 MOI concentration 24 hours after the end of the 
transfection with miR-210. The day of transduction PACs were washed with PBS and EFNA3 (or 
CTRL) lentivirus plus polybrene (final concentration 8 μg/mL) (Sigma) were added. 4 hours after 
infection, an equal volume of complete PACs medium was added. Cells were selected with 
puromycine (1 μg/mL) (Calbiochem) after 48 hours from transduction. 
 
Surgical model of limb ischemia in mice 
The experiments involving mice were performed in accordance with the Animal (Scientific 
Procedures) Act (UK) of 1986 prepared by the Institute of Laboratory Animal Resources and 
covered under the UK Home Office Project licence PPL/30/2811 and personal licenses. 
Experiments were performed by a blind investigator. Three-month-old immunocompromised CD1-
Foxn1nu male mice (Charles River, United Kingdom; n=12–14 mice/group) or C57BL6 mice 
(Charles River, Italy, n=3-5/group) underwent surgical induction of unilateral limb ischemia (LI) by 
performing dissection of the left femoral artery, as we reported previously.70 Immediately after LI 
induction, CD1-Foxn1nu mice received 2x105 PACs from cord blood from 3 different donors, 
injected into the adductor muscle. The superficial blood flow to both ischemic and non-ischemic 
feet was measured using a high-resolution laser color Doppler imaging system (Moor LDI2, Moor 
Instruments) in anesthetised animals with 1% isoflurane at days 0, 7, 14 and 21 after induction of 
limb ischemia. The ratio of blood flow between the ischemic and contralateral foot was calculated 
to use as an index of percentage blood flow recovery. At day 21, mice under terminal anaesthesia 
were perfusion-fixed successively with 6 mL of 0.05 M EDTA and 10 mL of 10% formalin solution. 
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Limb muscles were harvested and stored in PFA 4% overnight at room temperature then washed 
with PBS and finally treated with 30% sucrose overnight at 4°C. The tissue samples were then 
embedded in optical cutting temperature (OCT) compound and stored at −80°C until histological 
and immunohistochemical analyses. C57BL6 mice were used for plasma miR experiments, as 
previously reported.71 
 
Immunohistology analysis on ischemic limb muscles 
The functional impact of engineered PACs on treatment of CD1-Foxn1nu ischemic mice was 
assessed by measuring capillaries and arterioles density in the adductor muscle. Eight-
micrometer-thick muscle sections were stained using biotin-conjugated Isolectin B4 (from 
GriffoniaSimplicifolia; Thermo Fisher Scientific) and streptavidin-conjugated Alexa 488 (Thermo 
Fisher Scientific) antibodies to detect capillaries. Arterioles were identified by staining of α-smooth 
muscle actin (α- SMA-Cye3, Sigma) and Wheat germ agglutinin-Alexa 647 (Thermo Fischer 
Scientific) was used to count the muscle fibres. Nuclei were stained with DAPI (4′,6-diamidino-2-
phenylindole). The slides were mounted using Fluoromount-G (eBioscience). The relative number 
of positive cells was counted in ten randomly selected high-power fields (magnification 200×) using 
a Zeiss inverted fluorescence microscope. Analyses were performed using muscles from eight 
mice per group. Capillary density was expressed in as capillary number to myofibre number ratio. 
Arteriole density was expressed as number per mm square. Quantification was conducted by 
investigator blinded. 
 
Statistical analyses 
Data are presented as mean±SEM and N refers to the number of donors of cells for in vitro 
experiments and number of animals for the in vivo analyses that are indicated in the figure 
legends. Statistical analyses and graphical representations were performed with appropriate 
software (GraphPad Prism). For molecular characterization and functional assessment of PACs, 
paired t test was used. Significance level was set at p<0.05. For statistical comparison in animal 
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studies, correlated outcome analysis was used to measure differences in between groups in blood 
flow recovery in the in vivo model of mouse critical limb ischemia. For histology analysis of capillary 
and arteriole density, one-way ANOVA with post-hoc Dunnett’s test was used.  
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Figure legends 
Figure 1. Hypoxia enhances miR-210 expression in culture-selected human PACs from 
peripheral blood. A) Cytofluorimetric characterization of peripheral blood (PB)-PACs. The bar 
graph shows the percentage of cells positive for hematopoietic cell marker CD45, pro-angiogenic 
cell markers CD34 and KDR, and monocyte marker CD14 (N=4 donors). B) Bar graph of average 
relative expression of (i) primary (pri)-miR-210 and (ii) mature miR-210 in PB-PACs to U6 snRNA 
which was used as a normalyzer; (iii) miR-210 expression vs. cel-39 spike-in gene in the 
unfractionated cell medium (CCM) of PB-PACs and (iv) in its extracellular vesicles (EVs); PACs 
were cultured 48 hours under normoxia (white bars) or hypoxia (grey bars, at 1%O2); *p<0.05 and 
**p<0.01 vs. normoxia, N=4 donors. 
 
Figure 2. miR-210 affects the migratory capacity and morphology of PB-PACs. A) Bar graph 
shows the capacity of PB-PACs engineered with pre- or anti-miR-210 to migrate toward SDF-1 
(CXCL-12) or in the absence of chemoattratant (vehicle). *p<0.05, **p<0.01 ***p<0.001 vs. vehicle; 
#p<0.05, ##p<0.01 vs. SCR. N=6 donors. B) Alteration of cell shape in response to miR-210 
modulation. Representative images of phalloidin staining: round shaped cells are indicated by 
yellow arrows. Scale bar 50 µm. Bar graph indicates  the average number of round shaped cells , 
*p<0.05. N=5 donors.  
 
Figure 3. miR-210 mediates PB-PACs interaction with endothelial cells. A) miR-210-
transfected-PB-PAC adhesion assay to human umbilical vein endothelial cells (HUVECs). Bar 
graph of average cell number (left) and representative images (right, scale bar 100µm). N=3 
donors; B) Bar graph of average intersections of HUVECs cultured in the presence of engineered 
PB-PACs (bottom panel) and representative images (upper panels, scale bar 100µm). Red= 
PKH26 dye (HUVECs); Green=PKH67 dye (PACs). N=4 donors. *p<0.05; ***p<0.001  
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Figure 4. Analysis of coding and non-coding EFNA3 isoforms following miR-210 
modulation. A) The expression of both coding and non-coding EFNA3 has been analyzed 
following miR-210 modulation in PB-PACs under normoxia and hypoxia. Real time q-PCR showed 
no mRNA modulation for coding (i) and non-coding EFNA3 over UCB housekeeping gene. 
N=4donors). B) Coding EFNA3 quantification by immunofluorescence staining confirmed EFNA3 is 
controlled by miR-210 modulation under normoxia but not hypoxia. N=4 donors, ** p<0.01 vs. SCR 
normoxia and pre-miR-210 normoxia. 
 
Figure 5. mir-210 over-expression mediates PB-PACs migratory and adhesive functions 
which are impaired by concomitant EFNA3 over-expression. A) Analysis of miR-210 
expression in PACs infected for 24h with EFNA3 bearing lentivirus (LV) and trasfected with pre-
miR-210. Bars represent treatment respectively with empty vector lentivirus (white bar), empty 
vector lentivirus + pre-miR-210 (grey bar), EFNA3 lentivirus (orange bar) and EFNA3 lentivirus + 
pre-miR-210 (red bar). Data expressed as mean 2ddCts±SEM vs. U6 snRNA. Concentration of 
viral particles 1 MOI. N=5 donors. *p<0.05, **p<0.01. B) Analysis of EFNA3 mRNA by qPCR in 
PACs treated as described in A). Data expressed as mean 2ddCts±SEM vs. U6 snRNA. N=4 
donors. *p<0.05. Lentivirus-mediated EFNA3 overexpression in PB-PACs abrogated the positive 
impacts induced by miR-210 overexpression on migration (C) and adhesion (D). For panel C) 
*p<0.05 vs. vehicle, #p<0.05 vs. SCR. N=4 donors. For panel D) *p<0.05, **p<0.01, ***p<0.001; 
N=5 donors 
 
Figure 6. UBC-PACs engineered ex vivo to overexpress miR-210 show an higher therapeutic 
potential for vascular repair in an immunocompromised mouse model of unilateral limb 
ischemia. UBC-PACs were engineered ex vivo with scramble control (SCR), pre- or anti miR-210. 
Engineered UBC-PACs or fresh cell medium were injected in the ischemic adductor muscle of 
mice with surgically induced unilateral limb ischemia.A) Postischemic blood flow recovery: (i) Time 
course of blood flow recovery (calculated as the ratio of blood flow in ischemic to contralateral foot) 
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(N=12–14/group), (ii) representative color laser Doppler flowmetry images at 0 and 21 days from 
surgery. B)Analyses of capillary and arteriole density in ischemic muscles: (i) bar graphs showing 
capillary and arteriole (≤20 μm diameter) density in ischemic adductor muscles at 21 days 
postischemia (N=8-10/group). (ii) Representative ischemic muscle sections stained with the 
endothelial marker isolectin B4 (green fluorescent) and an antibody for α-smooth muscle actin (red 
fluorescent) to identify smooth muscles cells in the arterial wall (scale bar, 100 µm). Arterioles are 
shown by white arrows. Data are expressed as mean±SEM. * p<0.05, **p<0.01, PACs + pre-miR-
210 vs. medium; † †, p<0.01, PACs + pre-miR-210 vs. PACs + SCR; #, p<0.05, PACs + pre-miR-
210 vs. PACs + anti-miR-210. 
